Skip to main content

Advertisement

SpringerLink
Log in

Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?

  • Regulatory Note
  • Published:
The AAPS Journal Aims and scope Submit manuscript

An Erratum to this article was published on 12 August 2015

Abstract

CT-P13, the world’s first biosimilar monoclonal antibody to infliximab, was approved for marketing in South Korea for all the six indications of infliximab, which Europe may follow, although the product was tested only in rheumatoid arthritis (RA) with a limited pharmacokinetic comparison in ankylosing spondylitis. However, the extrapolation of the efficacy and safety findings of CT-P13 in RA to the other indications appears scientifically challenging when assessed by the current regulatory requirements. RA is not a sensitive clinical model to detect potential differences between CT-P13 and infliximab, and other mechanisms of action than antagonizing tumor necrosis factor α appear to be also important, which could be different by the approved indications. Furthermore, the immunogenicity and safety profiles of CT-P13 were not sufficiently characterized in that immunogenicity potential was lowest in RA, which was even further suppressed by the concomitant use of methotrexate. Extrapolation of the safety and efficacy data in one indication to another may be inappropriate for biosimilars unless backed up by strong scientific justification, which may include the mechanistic exposure–relationship approach. Therefore, regulatory agencies need to exercise caution before granting extrapolated indications to biosimilars.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  1. Biosimilar News. World’s first biosimilar antibody is approved in Korea 7/23/2012. http://www.biosimilarnews.com/worlds-first-biosimilar-antibody-is-approved-in-korea (2012) Accessed 2 Mar 2013

  2. European Medicines Agency. European Medicines Agency recommends approval of first two monoclonal-antibody biosimilars. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001837.jsp&mid=WC0b01ac058004d5c1 (2013). Accessed 29 Jul 2013

  3. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–20. doi:10.1136/annrheumdis-2012-203090.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–12. doi:10.1136/annrheumdis-2012-203091.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Korea Food and Drug Administration. National Institute of Food and Drug Safety Evaluation. Guidelines on the evaluation of biosimilar products. Chungcheongbuk-do: Korea Food and Drug Administration; 2010

  6. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva: World Health Organization; 2009

  7. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product (draft). Rockville: Food and Drug Administration; 2012

  8. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies (EMA/CHMP/BMWP/403543/2010). London: European Medicines Agency; (2010)

  9. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry. Non-inferiority clinical trials (Draft). Rockville: Food and Drug Administration; 2010

  10. Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol. 2010;28(1):28–31. doi:10.1038/nbt0110-28.

    Article  CAS  PubMed  Google Scholar 

  11. Centocor Inc. Label for Infliximab (REMICADE). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5345lbl.pdf (2013). Accessed 2 Sep 2013

  12. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343(22):1594–602. doi:10.1056/NEJM200011303432202.

    Article  CAS  PubMed  Google Scholar 

  13. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432–43. doi:10.1056/NEJM199710093371502.

    Article  CAS  PubMed  Google Scholar 

  14. Golay J, Introna M. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys. 2012;526(2):146–53. doi:10.1016/j.abb.2012.02.011.

    Article  CAS  PubMed  Google Scholar 

  15. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9. doi:10.1016/S0140-6736(02)08512-4.

    Article  CAS  PubMed  Google Scholar 

  16. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–405. doi:10.1056/NEJM199905063401804.

    Article  CAS  PubMed  Google Scholar 

  17. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–85. doi:10.1056/NEJMoa030815.

    Article  CAS  PubMed  Google Scholar 

  18. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35.

    Article  CAS  PubMed  Google Scholar 

  19. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121(5):1088–94. doi:10.1053/gast.2001.28674.

    Article  CAS  PubMed  Google Scholar 

  20. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New Engl J Med. 1999;340(4):253–9. doi:10.1056/NEJM199901283400401.

    Article  CAS  PubMed  Google Scholar 

  21. van den Brande JMH, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology. 2003;124(7):1774–85. doi:10.1016/S0016-5085(03)00382-2.

    Article  PubMed  Google Scholar 

  22. Smeets TJM, Kraan MC, van Loon ME, Tak P-P. Tumor necrosis factor α blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum. 2003;48(8):2155–62. doi:10.1002/art.11098.

    Article  CAS  PubMed  Google Scholar 

  23. Horiuchi T, Mitoma H, Harashima S-i, Tsukamoto H, Shimoda T. Transmembrane TNF-α: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49(7):1215–28. doi:10.1093/rheumatology/keq031.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Reichert JM. Next generation and biosimilar monoclonal antibodies: essential considerations towards regulatory acceptance in Europe. February 3–4, 2011, Freiburg, Germany. MAbs. 2011;3(3):223–40. doi:10.4161/mabs.3.3.15475.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Schellekens H. Biosimilar therapeutics—what do we need to consider? NDT Plus. 2009;2(Suppl_1):i27–36. doi:10.1093/ndtplus/sfn177.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant. 2006;21 Suppl 5:v9–v12. doi:10.1093/ndt/gfl476.

    Article  CAS  PubMed  Google Scholar 

  27. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005;18(3):473–80. doi:10.1016/j.beha.2005.01.016.

    Article  CAS  PubMed  Google Scholar 

  28. Baert F, Noman M, Vermeire S, van Assche G, D’Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8. doi:10.1056/NEJMoa020888.

    Article  CAS  PubMed  Google Scholar 

  29. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31–15. doi:10.1016/j.jaad.2006.07.017.

    Article  PubMed  Google Scholar 

  30. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–74. doi:10.1016/S0140-6736(05)67566-6.

    Article  CAS  PubMed  Google Scholar 

  31. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932–9. doi:10.1016/S0140-6736(99)05246-0.

    Article  CAS  PubMed  Google Scholar 

  32. Flood J. Tumor necrosis factor inhibitors in the treatment of chronic inflammatory diseases. A review of immunogenicity and potential implications. Manag Care. 2009;18(4 Suppl 3):1–5.

    PubMed  Google Scholar 

  33. Gecse KB, Khanna R, van den Brink GR, Ponsioen CY, Lowenberg M, Jairath V, et al. Biosimilars in IBD: hope or expectation? Gut. 2013;62(6):803–7. doi:10.1136/gutjnl-2012-303824.

    Article  CAS  PubMed  Google Scholar 

  34. Danese S, Gomollon F, Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7(7):586–9. doi:10.1016/j.crohns.2013.03.011.

    Article  PubMed  Google Scholar 

  35. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther. 2011;13(3):112. doi:10.1186/ar3310.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  36. Lee H, Yim DS, Zhou H, Peck CC. Evidence of effectiveness: how much can we extrapolate from existing studies? AAPS J. 2005;7(2):E467–74. doi:10.1208/aapsj070247.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Dorner T, Strand V, Castaneda-Hernandez G, Ferraccioli G, Isaacs JD, Kvien TK, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013;72(3):322–8. doi:10.1136/annrheumdis-2012-202715.

    Article  PubMed  Google Scholar 

  38. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76. doi:10.1056/NEJMoa050516.

    Article  CAS  PubMed  Google Scholar 

  39. van der Heijde D, Dijkmans B, Geusens P, Sieper J, Dewoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–91. doi:10.1002/art.20852.

    Article  PubMed  Google Scholar 

  40. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52(4):1227–36. doi:10.1002/art.20967.

    Article  CAS  PubMed  Google Scholar 

  41. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150–7. doi:10.1136/ard.2004.032268.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–42. doi:10.1016/j.jaad.2004.02.021.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

The author has no conflict of interest to declare.

Author information

Authors and Affiliations

  1. Clinical Trials Center, Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu Seoul, 110-744, South Korea

    Howard Lee

Authors
  1. Howard Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howard Lee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, H. Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?. AAPS J 16, 22–26 (2014). https://doi.org/10.1208/s12248-013-9534-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-013-9534-y

KEY WORDS

Search

Navigation